Organogenesis Holdings Inc. (Nasdaq: ORGO) announced the publication of results from a randomized controlled trial evaluating its Affinity product in ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE